Xen­cor, UCLA to part­ner for new ther­a­peu­tic an­ti­bod­ies; Schrödinger ex­pands part­ner­ship with Google Cloud

Seek­ing to build on the 20 clin­i­cal-stage drug can­di­dates al­ready in its pipeline, Cal­i­for­nia on­col­o­gy and au­toim­mune dis­ease-fo­cused biotech Xen­cor an­nounced on Thurs­day a part­ner­ship with near­by UCLA and the uni­ver­si­ty’s Tech­nol­o­gy De­vel­op­ment Group.

The two will col­lab­o­rate to de­vel­op nov­el ther­a­peu­tic an­ti­bod­ies, pair­ing nov­el tar­gets pro­posed by sci­en­tists at UCLA with Xen­cor’s XmAb tech­nol­o­gy plat­forms that en­gi­neer mon­o­clon­al an­ti­bod­ies to cre­ate new pro­tein struc­tures. No fi­nan­cial terms of the agree­ment were dis­closed, but any se­lect­ed drug can­di­dates re­sult­ing from the part­ner­ship will use a frame­work of “pre­de­fined terms to en­ter spon­sored re­search agree­ments and po­ten­tial li­cense agree­ments,” the or­ga­ni­za­tions said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER